University of Toledo, Toledo, OH
Copyright 2016, American College of Chest Physicians. All Rights Reserved.
SESSION TITLE: Mechanical Ventilation & Respiratory Failure II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Corticosteroids are commonly administered in critically ill patients for a variety of reasons. They were estimated to be used in about 26% of critically ill patients. Controversies have always surrounded their outcomes in the ICU. While they have been shown to increase death in Intensive Care Unit - acquired pneumonia, they have been proposed to prevent hospital acquired pneumonia in intubated patients with multiple trauma. In the Society of Critical Care Medicine guidelines, it was recommended to consider hydrocortisone treatment for patients with septic shock with no mortality benefit. Herein, we present a sample of an ongoing analysis of the use of hydrocortisone and the risk of Ventilator Associated Events compared to other steroids in our university hospital. Ventilator Asscoiated Events (VAE) defined by the CDC National Healthcare Safety Network developed in 2013.
METHODS: The dataset consisted of a sample of 858 mechanically-ventilated patients. According to hospital surveillance records, 152 patients met CDC-defined criteria for a VAE. Dexamethasone, methylprednisolone, prednisone, and hydrocortisone usage during the intubation period was also collected among each group. The data was analyzed using Chi-square statistics and an alpha level of 0.05 was considered statistically significant.
RESULTS: Of the total 858 patients, 706 where in the non-VAE group. Of those, 62 (8.8%) patients received dexamethasone, 133(18.8%) where treated with methylprednisolone, 72 (10.2%) with prednisone and 68 (9.6%) patients with hydrocortisone. In the VAE group (N=152), the numbers where as follows: 14 for dexamethasone (9.2%), 39 for methylprednisolone (25.7%), 16 for prednisone (10.5%) and 41 for hydrocortisone (27%). Only hydrocortisone treated group showed a significant relationship in regards to the development of VAE (X2 = 33.9, P < 0.001). No statistical significance was noted with the other steroids. The was no difference in the SOFA score or the pressor use among all steroid groups including hydrocortisone group.
CONCLUSIONS: Postulations behind the lack of favor of hydrocortisone could include the weaker anti-inflammatory of this steroid when compared to others. Also, patients who need hydrocortisone therapy would be generally more critically ill so the need of hydrocortisone therapy could implement a negative prognostic factor for the development of VAE. However, in our analysis the SOFA score and vasopressor use were similar among all groups.
CLINICAL IMPLICATIONS: In our study we found that the use of hydrocortisone was significantly higher in the VAP population. This can be related to hydrocortisone being the steroid of choice in septic & adrenally insuffecient patients. Albeit hydrocortisone's immunosuppressive potency is lower compared to its peer steroids, this doesn't seem to play a major role when it comes to VAE in our population.
DISCLOSURE: The following authors have nothing to disclose: Nawaf Almeshal, Talia Tarazi, William Barnett, Aahd Kubbara, Wail Alamoudi, Reyna Altook, Rasha Nakity, Asif Iqbal, Ajit Ramadugu, Shahnaz Rehman, Fadi Safi, Ragheb Assaly
No Product/Research Disclosure Information
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.